Together, these data identify the NKG2A/HLA-E axis as a novel dependency, at least in CAR-T-treated B-ALL cells, and nominate this pathway as a potential target which, when inhibited, may potentiate the efficacy of CAR-T therapy. Here, KLRC1 is linked to acute lymphoblastic leukemia.